Pilot Study Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of the Combination of Exemestane and Tamoxifen

Clinical Cancer Research

Volumn 10, Issue 6, 2004, Pages 1943-1948

  Rivera, Edgardo ^a   Valero, Vicente ^a   Francis, Deborah ^a   Asnis, Aviva G ^b   Schaaf, Larry J ^b   Duncan, Barbara ^b   Hortobagyi, Gabriel N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; ESTRADIOL; ESTRONE; ESTRONE SULFATE; EXEMESTANE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ADULT; AGED; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE PAIN; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; ESTROGEN BLOOD LEVEL; FATIGUE; FEMALE; HORMONE SENSITIVITY; HOT FLUSH; HUMAN; MONOTHERAPY; MYALGIA; NAIL DISEASE; NAIL LESION; NAUSEA; PILOT STUDY; PRIORITY JOURNAL; VAGINA BLEEDING;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANDROSTADIENES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; ESTRADIOL; ESTRONE; FEMALE; HISTORY, 18TH CENTURY; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PILOT PROJECTS; TAMOXIFEN;

EID: 1642397469     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-1005-03     Document Type: Article

References (23)

1. Goldhirsch A, Gelber RD. Endocrine therapies of breast cancer. Semin Oncol 1996;23:494-505.
2. Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a randomized double-blind trial. J Clin Oncol 2001;18:1399-1411.
3. Paridaens R, Dirix L, Lohrisch C, et al. Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone treatment for postmenopausal women with metastatic breast cancer. Ann Oncol 2003;14:1391-8.
4. Lønning PE, Bajetta E, Murray R, et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol 2000;18:2234-44.
5. Brodie AMH, Garrett WM, Hendrickson JR. Inactivation of aromatase in vitro by 4-hydroxy-4-androstene-3,17-dione and 4-acetoxy-4-androstene-3, 17-dione and sustained effects in vivo. Steroids 1981; 38:693-702.
6. Miller WT. Aromatase inhibitors in the treatment of advanced breast cancer. Cancer Treat Rev 1989;16:83-93.
7. Buzdar AU, Robertson JFR, Eirmann W, Nabholtz J-M. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole and exemestane. Cancer (Phila) 2002;95:2006-16.
8. Lu Q, Liu Y, Long BJ, Grigoryev D, Gimbel M, Brodie A. The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer. Breast Cancer Res Treat 1999;57:183-92.
9. Dowsett M, Pfister C, Johnston SRD, et al. Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer. Clin Cancer Res 1999;5:2338-43.
10. Dowsett M, Cuzick J, Howell A, Jackson I; ATAC Trialists' Group. Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and Tamoxifen Alone or in Combination' (ATAC) trial. Br J Cancer 2001;85:317-24.
11. Zaccheo T, Giudici D, Di Salle E. Inhibitory effect of combined treatment with the aromatase inhibitor exemestane and tamoxifen on DMBA-induced mammary tumors in rats. J Steroid Biochem Mol Biol 1993;44:677-80.
12. Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN. Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol 1995;13:513-29.
13. Zubrod CG, Schneiderman M, Frei E, et al. Appraisal of methods for the study of chemotherapy of cancer in man: comparative therapeutic trial of nitrogen mustard and triethylene thioposphoramide. J Chronic Dis 1960;11:7-33.
14. Morello KC, Wurz GT, DeGregorio MW. Pharmacokinetics of selective estrogen receptor modulators. Clin Pharmacokinet 2003;42:361-72.
15. Cenacchi V, Barattè S, Cicioni P, Frigerio E, Long J, James C. LC-MS-MS determination of exemestane in human plasma with heated nebulizer interface following solid-phase extraction in the 96 well plate format. J Pharm Biomed Anal 2000;22:451-60.
16. Johannessen DC, Engan T, Di Salle E, et al. Endocrine and clinical effects of exemestane (PNU-155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res 1997;3:1101-8.
17. Langecker P, Blanchett D, Lang W, et al. Phase I, open-label, randomized crossover study of the pharmacokinetic interaction of toremifene and atamestane (Biomed 777) in healthy postmenopausal women [poster]. San Antonio Breast Cancer Meeting; 2002 Dec. 11-14; Hingham, MA: Kluwer Academic Publisher, 2002.
18. Hutson PR, Love RR, Cleary JF, Kim K. Pharmacokinetic and pharmacodynamic interaction of adjuvant tamoxifen and exemestane in postmenopausal women treated for early stage breast cancer [poster]. San Antonio Breast Cancer Meeting; 2002 Dec. 11-14; Hingham, MA: Kluwer Academic Publisher, 2002.
19. Jannuzzo MG, Spinelli R, Poggesi I, Cicioni P, Böttiger Y, Bertilsson L. Inhibition of CYP34A does not influence Aromasin (exemestane, EXE) pharmacokinetics (PK) in healthy postmenopausal volunteers (HPV). Eur J Cancer 1999;35(Suppl 4):S294.
20. Spinelli R, Jannuzzo MG, Poggesi I, et al. Pharmacokinetics (PK) of Aromasin (exemestane, EXE) after single and repeated doses in healthy postmenopausal volunteers (HPV). Eur J Cancer 1999;35(Suppl 4):S295.
21. ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131-9.
22. Jelovac D, Long B, Sabnis G, et al. Preclinical studies evaluating the anti-tumor effects of exemestane using the intratumoral aromatase postmenopausal breast cancer model [poster]. San Antonio Breast Cancer Meeting; 2002 Dec. 11-14; Hingham, MA: Kluwer Academic Publisher, 2002.
23. Dimitrakakis C, Zhou J, Wang J, et al. A physiologic role for testosterone in limiting estrogenic stimulation of the breast. Menopause 2003;10:292-8.